839 related articles for article (PubMed ID: 18097455)
61. [Emetogenic potential of antineoplastic agents based on clinical trials in Japan].
Watanabe T; Handa S; Kato Y
Gan To Kagaku Ryoho; 2015 Mar; 42(3):335-41. PubMed ID: 25812503
[TBL] [Abstract][Full Text] [Related]
62. [Evidence-based management of nausea and vomiting].
Ishiguro H; Nambu Y; Maekawa Y; Adachi S
Gan To Kagaku Ryoho; 2006 May; 33(5):701-6. PubMed ID: 16685175
[TBL] [Abstract][Full Text] [Related]
63. A survey of antiemetic use in children with cancer.
van Hoff J; Hockenberry-Eaton MJ; Patterson K; Hutter JJ
Am J Dis Child; 1991 Jul; 145(7):773-8. PubMed ID: 2058609
[TBL] [Abstract][Full Text] [Related]
64. [The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting].
Kreutz S
Pharm Unserer Zeit; 2007; 36(5):389-92. PubMed ID: 17722146
[No Abstract] [Full Text] [Related]
65. History of the development of antiemetic guidelines at Mayo Clinic Rochester.
Loprinzi CL; Alberts SR; Christensen BJ; Hanson LJ; Farley DR; Broers JK; Betcher DL; Grady RE; Southorn PA; Johnson TM; Perez EA
Mayo Clin Proc; 2000 Mar; 75(3):303-9. PubMed ID: 10725961
[TBL] [Abstract][Full Text] [Related]
66. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Hawkins R; Grunberg S
Clin J Oncol Nurs; 2009 Feb; 13(1):54-64. PubMed ID: 19193549
[TBL] [Abstract][Full Text] [Related]
67. Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients.
Shankar A; Roy S; Malik A; Julka PK; Rath GK
Asian Pac J Cancer Prev; 2015; 16(15):6207-13. PubMed ID: 26434818
[TBL] [Abstract][Full Text] [Related]
68. Evidence-based recommendations for the use of antiemetics in radiotherapy.
Maranzano E; Feyer PCh; Molassiotis A; Rossi R; Clark-Snow RA; Olver I; Warr D; Schiavone C; Roila F;
Radiother Oncol; 2005 Sep; 76(3):227-33. PubMed ID: 16150504
[TBL] [Abstract][Full Text] [Related]
69. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
70. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.
Holdsworth MT; Vo-Nguyen T
Ann Pharmacother; 2005 Nov; 39(11):1903-10. PubMed ID: 16204394
[TBL] [Abstract][Full Text] [Related]
71. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.
Perwitasari DA; Gelderblom H; Atthobari J; Mustofa M; Dwiprahasto I; Nortier JW; Guchelaar HJ
Int J Clin Pharm; 2011 Feb; 33(1):33-43. PubMed ID: 21365391
[TBL] [Abstract][Full Text] [Related]
72. The difficult trials.
Herrstedt J
Onkologie; 2009 Feb; 32(1-2):7-8. PubMed ID: 19209012
[No Abstract] [Full Text] [Related]
73. Concordance between substance P levels and antiemetic guidelines.
Higa GM; Auber ML; Altaha R; Kurian S; Hobbs G
J Support Oncol; 2009; 7(4):138-42. PubMed ID: 19731580
[TBL] [Abstract][Full Text] [Related]
74. A new class of antiemetic agents on the horizon.
Rittenberg CN
Clin J Oncol Nurs; 2002; 6(2):103-4. PubMed ID: 11889671
[TBL] [Abstract][Full Text] [Related]
75. [Insufficient evidence in prophylactic therapy of chemotherapy-induced nausea and vomiting in children and adolescents].
Eliasen A; Callesen MT; Dalhoff KP; Rechnitzer C; Schmiegelow K; Schrøder H; Tuckuviene R; Holst H
Ugeskr Laeger; 2018 Aug; 180(35):. PubMed ID: 30152323
[TBL] [Abstract][Full Text] [Related]
76. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
77. International patterns of practice in the management of radiation therapy-induced nausea and vomiting.
Dennis K; Zhang L; Lutz S; van Baardwijk A; van der Linden Y; Holt T; Arnalot PF; Lagrange JL; Maranzano E; Liu R; Wong KH; Wong LC; Vassiliou V; Corn BW; De Angelis C; Holden L; Wong CS; Chow E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e49-60. PubMed ID: 22704982
[TBL] [Abstract][Full Text] [Related]
78. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
79. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
[No Abstract] [Full Text] [Related]
80. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
